{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:34:40Z","timestamp":1766086480749},"reference-count":14,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2923,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/jto.0b013e31815ba7d0","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T10:12:44Z","timestamp":1209895964000},"page":"1112-1116","source":"Crossref","is-referenced-by-count":21,"title":["Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"2","author":[{"given":"Angela M.","family":"Davies","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex S.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel A.","family":"Beckett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Primo N.","family":"Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derick H.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e31815ba7d0_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","article-title":"Development of the proteasome inhibitor PS-341","volume":"7","author":"Adams","year":"2002","journal-title":"Oncologist"},{"issue":"7 Suppl","key":"10.1097\/JTO.0b013e31815ba7d0_bib2","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.3816\/CLC.2005.s.011","article-title":"The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer","volume":"2","author":"Edelman","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib3","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib4","first-page":"741","article-title":"Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells","volume":"19","author":"Yunmbam","year":"2001","journal-title":"Int J Oncol"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib5","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib6","article-title":"Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC)","volume":"22","author":"Gumerlock","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.athoracsur.2003.11.021","article-title":"Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002","volume":"78","author":"Visbal","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib8","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [see comment]","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib9","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib10","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1200\/jco.2004.22.14_suppl.7106","article-title":"The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): final results of a phase I California Cancer Consortium study (Abstract)","volume":"22","author":"Davies","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3816\/CLC.2006.n.021","article-title":"Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer","volume":"7","author":"Davies","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib12","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1158\/1535-7163.MCT-07-0167","article-title":"TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib","volume":"6","author":"Voortman","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib13","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-06-4274","article-title":"The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells","volume":"67","author":"Liu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e31815ba7d0_bib14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ajh.20961","article-title":"Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients","volume":"82","author":"Zangari","year":"2007","journal-title":"Am J Hematol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415311825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415311825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T23:52:10Z","timestamp":1546041130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415311825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S1556086415311825"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e31815ba7d0","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}